Bardia Nourbakhsh1, Julia Nunan-Saah2, Amir-Hadi Maghzi3, Laura J Julian4, Rebecca Spain5, Chengshi Jin6, Ann Lazar6, Daniel Pelletier7, Emmanuelle Waubant8. 1. Department of Neurology, University of California San Francisco, San Francisco, USA. Electronic address: bardia.nourbakhsh@ucsf.edu. 2. Palo Alto University, Palo Alto, CA, USA. 3. Department of Neurology, University of California San Francisco, San Francisco, USA. 4. Department of Internal Medicine, University of California San Francisco, San Francisco, CA, USA. 5. Department of Neurology, Oregon Health and Science University, OR, USA. 6. Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA. 7. Department of Neurology, University of Southern California, Los Angeles, CA, USA. 8. Department of Neurology, University of California San Francisco, San Francisco, USA; Department of Pediatrics, University of California San Francisco, San Francisco, USA.
Abstract
OBJECTIVES: Cognitive dysfunction in multiple sclerosis (MS) has been primarily examined in patients with advanced disease. Our objective was to study the longitudinal associations between brain magnetic resonance imaging (MRI) metrics and neuropsychological outcomes in patients with early MS. METHODS: Relapsing MS patients within 12 months of onset were enrolled in a neuroprotection trial of riluzole versus placebo with up to 36 months of follow-up. MRI metrics included percent brain volume changes measured by SIENAX normalized measurements [normalized brain parenchymal volume (nBPV), normalized normal-appearing white and gray matter volume (nNAWMV and nGMV)] and T2 lesion volume (T2LV). A neuropsychological battery was performed annually. Mixed model regression measured time trends and associations between imaging and neuropsychological outcomes, adjusting for sex, age and education level. RESULTS: Forty-three patients (mean age 36 years; 31 females) were enrolled within 7.5 ± 4.9 months of disease onset. 11.6% of patients with baseline cognitive assessment met conservative criteria for cognitive impairment. Compared to placebo, riluzole had no significant effect on neuropsychological performance; thus, both groups were combined for the association analyses. Baseline T2LV predicted subsequent changes in PASAT (p=0.006) and SDMT (p=0.002) scores. Longitudinal changes of T2LV were associated with changes in CVLT-II (p<0.001). CONCLUSION: These findings suggest that cognitive impairment is relatively common in patients with very early MS. Baseline and longitudinal changes in the lesion load may be associated with some of the most frequently identified changes in cognitive function in MS.
OBJECTIVES:Cognitive dysfunction in multiple sclerosis (MS) has been primarily examined in patients with advanced disease. Our objective was to study the longitudinal associations between brain magnetic resonance imaging (MRI) metrics and neuropsychological outcomes in patients with early MS. METHODS: Relapsing MS patients within 12 months of onset were enrolled in a neuroprotection trial of riluzole versus placebo with up to 36 months of follow-up. MRI metrics included percent brain volume changes measured by SIENAX normalized measurements [normalized brain parenchymal volume (nBPV), normalized normal-appearing white and gray matter volume (nNAWMV and nGMV)] and T2 lesion volume (T2LV). A neuropsychological battery was performed annually. Mixed model regression measured time trends and associations between imaging and neuropsychological outcomes, adjusting for sex, age and education level. RESULTS: Forty-three patients (mean age 36 years; 31 females) were enrolled within 7.5 ± 4.9 months of disease onset. 11.6% of patients with baseline cognitive assessment met conservative criteria for cognitive impairment. Compared to placebo, riluzole had no significant effect on neuropsychological performance; thus, both groups were combined for the association analyses. Baseline T2LV predicted subsequent changes in PASAT (p=0.006) and SDMT (p=0.002) scores. Longitudinal changes of T2LV were associated with changes in CVLT-II (p<0.001). CONCLUSION: These findings suggest that cognitive impairment is relatively common in patients with very early MS. Baseline and longitudinal changes in the lesion load may be associated with some of the most frequently identified changes in cognitive function in MS.
Authors: Ludwig Rasche; Michael Scheel; Karen Otte; Patrik Althoff; Annemieke B van Vuuren; Rene M Gieß; Joseph Kuchling; Judith Bellmann-Strobl; Klemens Ruprecht; Friedemann Paul; Alexander U Brandt; Tanja Schmitz-Hübsch Journal: Front Neurol Date: 2018-08-29 Impact factor: 4.003
Authors: Jonathan D Santoro; Michael Waltz; Greg Aaen; Anita Belman; Leslie Benson; Mark Gorman; Manu S Goyal; Jennifer S Graves; Yolanda Harris; Lauren Krupp; Timothy Lotze; Soe Mar; Manikum Moodley; Jayne Ness; Mary Rensel; Moses Rodriguez; Teri Schreiner; Jan-Mendelt Tillema; Emmanuelle Waubant; Bianca Weinstock-Guttman; Brigitte F Hurtubise; Shelly Roalstad; John Rose; T Charles Casper; Tanuja Chitnis Journal: Neurology Date: 2020-07-20 Impact factor: 9.910
Authors: Tomas Uher; Jan Krasensky; Lukas Sobisek; Jana Blahova Dusankova; Zdenek Seidl; Eva Kubala Havrdova; Maria Pia Sormani; Dana Horakova; Tomas Kalincik; Manuela Vaneckova Journal: Ann Clin Transl Neurol Date: 2017-12-15 Impact factor: 4.511